Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients

NCT04291300 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Salivary Gland Cancer
Salivary Duct Carcinoma
Adenoid Cystic Carcinoma

Interventions

DRUG: Lutetium-177-PSMA-I&T

Sponsor

Radboud University Medical Center

Collaborators

[object Object]